---
search:
  boost: 3
---

# Neuropathic Pain

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                          | Generic Name                                                  | Quantity | Time (Days) |
|:-----------------------------------|:--------------------------------------------------------------|:--------:|:-----------:|
| Amitriptyline                      |                                                               |          |             |
| Carbamazepine                      |                                                               |          |             |
| Desipramine                        |                                                               |          |             |
| Doxepin 10, 25, 50, 75, 100, 150mg |                                                               |          |             |
| Doxepin Sol                        |                                                               |          |             |
| Duloxetine <sup>QL</sup>           | Duloxetine HCI Enteric Pellets Cap (all strengths excl 30 MG) |   204    |     102     |
| Duloxetine <sup>QL</sup>           | Duloxetine HCI Enteric Pellets Cap 30 MG                      |   306    |     102     |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 100 MG                                     |   204    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 300 MG                                     |   408    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Cap/Tab 400 MG                                     |   306    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Tab 600 MG                                         |   204    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Tab 800 MG                                         |   136    |     34      |
| Gabapentin <sup>QL</sup>           | Gabapentin Oral Soln 250 MG / 5 ML                            |   2448   |     34      |
| Imipramine                         |                                                               |          |             |
| Lidocaine Patch                    |                                                               |          |             |
| Nortriptyline                      |                                                               |          |             |
| Oxcarbazepine                      |                                                               |          |             |
| Pregabalin <sup>QL</sup>           | Pregabalin Cap (all strengths excl 225 MG & 300 MG)           |   102    |     34      |
| Pregabalin <sup>QL</sup>           | Pregabalin Cap 225 MG & 300 MG                                |    68    |     34      |
| Ztlido <sup>ST</sup>               |                                                               |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Gralise       |              |          |             |
| Horizant      |              |          |             |
| Pregabalin ER |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Criteria

- Must have had an inadequate clinical response of at least ^^30 days^^ with generic Lidocaine patch

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^two preferred^^ drugs in different drug classes
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=38){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=45){ :target="_blank" rel="noopener"} 

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=17){ :target="_blank" rel="noopener"} 

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
